Literature DB >> 10585787

Estimating the true cost of amphotericin B.

J H Rex, T J Walsh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10585787     DOI： 10.1086/313555

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  8 in total

1.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

2.  An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.

Authors:  Coleman Rotstein; Michel Laverdière; Anne Marciniak; Farzad Ali
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-09       Impact factor: 2.471

3.  Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections.

Authors:  Joseph L Kuti; Srividya Kotapati; Peter Williams; Blair Capitano; Charles H Nightingale; David P Nicolau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Comparison of adverse events and hospital length of stay associated with various amphotericin B formulations: sequential conventional amphotericin b/lipid versus lipid-only therapy for the treatment of invasive fungal infections in hospitalized patients.

Authors:  Rolin L Wade; Paresh Chaudhari; Jaime L Natoli; Robert J Taylor; Brian H Nathanson; David Horn
Journal:  P T       Date:  2013-05

5.  Cryptococcal antigen screening by lay cadres using a rapid test at the point of care: A feasibility study in rural Lesotho.

Authors:  Fernanda Rick; Aline Aurore Niyibizi; Amir Shroufi; Kazumi Onami; Sarah-Jane Steele; Malehlohonolo Kuleile; Innocent Muleya; Tom Chiller; Tiffany Walker; Gilles Van Cutsem
Journal:  PLoS One       Date:  2017-09-06       Impact factor: 3.240

6.  Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups.

Authors:  Rebecca S Campbell; Paresh Chaudhari; Harlen D Hays; Robert J Taylor; Brian H Nathanson; Samuel A Bozzette; David L Horn
Journal:  Clinicoecon Outcomes Res       Date:  2013-10-24

7.  Monetary costs and hospital burden associated with the management of invasive fungal infections in Mexico: a multicenter study.

Authors:  Dora Edith Corzo-León; Diana Perales-Martínez; Alexandra Martin-Onraet; Norma Rivera-Martínez; Adrian Camacho-Ortiz; Hiram Villanueva-Lozano
Journal:  Braz J Infect Dis       Date:  2018-11-02       Impact factor: 3.257

8.  Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections.

Authors:  Alyaa A Albadr; Ismaiel A Tekko; Lalitkumar K Vora; Ahlam A Ali; Garry Laverty; Ryan F Donnelly; Raghu Raj Singh Thakur
Journal:  Drug Deliv Transl Res       Date:  2021-07-23       Impact factor: 4.617
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.